Image_1_Effects of Allicin on Late Sodium Current Caused by ΔKPQ-SCN5A Mutation in HEK293 Cells.TIF by Yating Chen (6707360)

“…Application of Allicin 30 μM reduced the late sodium current (I_Na,L) of the Nav1.5 channel current encoded by ΔKPQ-SCN5A from 1.92 ± 0.12 to 0.65 ± 0.03 pA/pF (P < 0.01, n = 15), which resulted in the decrease of I_Na,L/I_Na,P (from 0.94% ± 0.04% to 0.32% ± 0.02%). …”

Image_2_Effects of Allicin on Late Sodium Current Caused by ΔKPQ-SCN5A Mutation in HEK293 Cells.TIF by Yating Chen (6707360)

“…Application of Allicin 30 μM reduced the late sodium current (I_Na,L) of the Nav1.5 channel current encoded by ΔKPQ-SCN5A from 1.92 ± 0.12 to 0.65 ± 0.03 pA/pF (P < 0.01, n = 15), which resulted in the decrease of I_Na,L/I_Na,P (from 0.94% ± 0.04% to 0.32% ± 0.02%). …”

Image_3_Effects of Allicin on Late Sodium Current Caused by ΔKPQ-SCN5A Mutation in HEK293 Cells.TIF by Yating Chen (6707360)

“…Application of Allicin 30 μM reduced the late sodium current (I_Na,L) of the Nav1.5 channel current encoded by ΔKPQ-SCN5A from 1.92 ± 0.12 to 0.65 ± 0.03 pA/pF (P < 0.01, n = 15), which resulted in the decrease of I_Na,L/I_Na,P (from 0.94% ± 0.04% to 0.32% ± 0.02%). …”

Image_4_Effects of Allicin on Late Sodium Current Caused by ΔKPQ-SCN5A Mutation in HEK293 Cells.TIF by Yating Chen (6707360)

“…Application of Allicin 30 μM reduced the late sodium current (I_Na,L) of the Nav1.5 channel current encoded by ΔKPQ-SCN5A from 1.92 ± 0.12 to 0.65 ± 0.03 pA/pF (P < 0.01, n = 15), which resulted in the decrease of I_Na,L/I_Na,P (from 0.94% ± 0.04% to 0.32% ± 0.02%). …”

Neuronal migration defects in the cortex and hippocampus of <i>R402H/+; Emx1-cre</i> mice. by Ines Leca (9592316)

“…(F) Graph showing the distribution of BrdU+ cells in the different layers of the hippocampus of P10 mice (n = 5). <i>R402H/+; Emx1-cre</i> mutants show a significant accumulation of cells in the OL, accompanied by a decrease in BrdU+ cells in the PCL in comparison to controls. …”

<i>S</i>. Typhimurium coordinates protein synthesis with protein folding capacity. by Carissa Chan (18310140)

Western blot analysis of tight junctional proteins occludin and claudin-5 in the CSF of mice with <i>A</i>. <i>cantonensis</i> infection. by Hung-Chin Tsai (673178)

“…Dexamethasone administration only had marginal effect on the decrease of expressions of BBB junctional proteins occludin and claudin-5. …”

Image5_ApoE isoform-dependent effects of xanthohumol on high fat diet-induced cognitive impairments and hippocampal metabolic pathways.JPEG by Payel Kundu (9019298)

Image5_ApoE isoform-dependent effects of xanthohumol on high fat diet-induced cognitive impairments and hippocampal metabolic pathways.JPEG by Payel Kundu (9019298)

Olfactory function test graphical summary and results. by Myeongguk Jeong (16386165)

Protection from R5- and X4- tropic HIV-1-mediated CD4⁺ T-cell loss in hu-BLT mice by Dual sh1005/sh516. by Gene-Errol E. Ringpis (106558)

“…Open circles: mCherry-marked. Error bars: mean + SEM in n = 5 and n = 4 for HIV-1_NFNSX- and HIV-1_NL4-3- infected mice, respectively. …”

Estimates of factors associated with suboptimal adherence among adolescents and adults in care and treatment. by Keith L. Gray (12279902)

Flow diagram depicting the records of eligible patients reviewed and included in the analyses. by Keith L. Gray (12279902)

Estimates of factors associated with death among adolescents and adults in care and treatment. by Keith L. Gray (12279902)

Estimates of factors associated with loss-to-follow-up among adolescents and adults in care and treatment. by Keith L. Gray (12279902)

Kaplan-Meier survival curves of admissions and mortality in patients with dementia with Lewy bodies, by medication use. by Shanquan Chen (3417512)

Characterization of demographical, clinical, and programmatic parameters of the cohort at baseline and outcomes at 24 months of follow-up. by Keith L. Gray (12279902)

Kaplan-Meier survivor estimate per age category and WHO clinical stage classification at registration in care and treatment among patients followed for 24 months. by Keith L. Gray (12279902)

Kaplan-Meier estimate of loss-to-follow-up per age category and WHO clinical stage classification at registration in care and treatment among patients followed for 24 months. by Keith L. Gray (12279902)

Kaplan-Meier probability of loss-to-follow-up and death among patients who were registered in 2016 and 2017 and followed for 24 months. by Keith L. Gray (12279902)